A detailed history of Ken Fisher (Fisher Asset Management, LLC) transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Fisher Asset Management, LLC holds 432,545 shares of SAGE stock, worth $2.43 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
432,545
Previous 436,421 0.89%
Holding current value
$2.43 Million
Previous $4.74 Million 34.21%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$7.02 - $13.08 $27,209 - $50,698
-3,876 Reduced 0.89%
432,545 $3.12 Million
Q2 2024

Aug 14, 2024

BUY
$10.58 - $17.9 $41,812 - $70,740
3,952 Added 0.91%
436,421 $4.74 Million
Q1 2024

May 09, 2024

BUY
$18.62 - $26.95 $10,129 - $14,660
544 Added 0.13%
432,469 $8.1 Million
Q4 2023

Mar 05, 2024

BUY
$17.1 - $22.26 $6,942 - $9,037
406 Added 0.09%
431,925 $9.36 Million
Q4 2023

Feb 06, 2024

BUY
$17.1 - $22.26 $545,490 - $710,094
31,900 Added 7.98%
431,519 $9.35 Million
Q3 2023

Nov 13, 2023

SELL
$16.75 - $48.98 $528,077 - $1.54 Million
-31,527 Reduced 7.31%
399,619 $8.22 Million
Q2 2023

Dec 12, 2023

BUY
$40.65 - $59.54 $1.28 Million - $1.88 Million
31,527 Added 7.89%
431,146 $20.3 Million
Q2 2023

Aug 08, 2023

BUY
$40.65 - $59.54 $399,304 - $584,861
9,823 Added 2.33%
431,146 $20.3 Million
Q1 2023

Dec 12, 2023

BUY
$37.27 - $46.57 $793,776 - $991,847
21,298 Added 5.33%
420,917 $17.7 Million
Q1 2023

May 01, 2023

SELL
$37.27 - $46.57 $643,019 - $803,472
-17,253 Reduced 3.93%
421,323 $17.7 Million
Q4 2022

Feb 03, 2023

SELL
$32.2 - $43.61 $200,863 - $272,039
-6,238 Reduced 1.4%
438,576 $16.7 Million
Q3 2022

Nov 08, 2022

BUY
$32.28 - $43.27 $14.4 Million - $19.2 Million
444,814 New
444,814 $17.4 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $333M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track Ken Fisher's Portfolio

Track Ken Fisher Portfolio

Follow Ken Fisher (Fisher Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.